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Background: Glycated haemoglobin (HbA1C) measurement is the currently accepted gold standard biochemical
indicator of long-term glycemic control in diabetic patients. The level of knowledge as well as the frequency of use
of this test among diabetic patients in Kenya is unknown. The current study aimed to document this among
patients attending the diabetes clinic at a national referral hospital in Kenya.
Methods: One hundred and ninety eight diabetic patients (59 male and 139 female) attending the outpatient
diabetes clinic at the Kenyatta National Hospital were interviewed on their level of knowledge and use of the
HbA1C test, as well as their last HbA1C level. The respondent answers were tabulated, analyzed and summarized.
The sample mean, standard deviation and percentages were calculated.
Results: Of the 198 patients interviewed, 11 (5.6%) had type I diabetes mellitus (DM) while 187 (94.4%) had type II
DM. One hundred and thirty four patients (67.7%) had heard of the HbA1C test while 64 patients (32.3%) had never
heard of the test. Forty patients (20.2%) had at one point done the test while 158 (79.8%) had never done the test.
The mean HbA1C level of the 40 patients who had at any one time done the test was 8.5 ± 1.7%, with more than
90% having HbA1C > 8%.
Conclusion: Using self-reported accounts, the current study indicates inadequate knowledge and infrequent testing
of HbA1C among diabetic outpatients in Kenya. This lack of knowledge and awareness may lead to increased
susceptibility to the development of diabetic complications, and potentially higher healthcare costs among these
patients. It is our recommendation that policy makers focus on strategies that address HbA1C test accessibility in
Kenya, including financial coverage by the national insurance to access the test in public facilities, so as to
effectively monitor and combat DM.
Keywords: HbA1C, Glycemic monitoring, Availability, Knowledge awareness and practices (KAP), Diabetes mellitus
(DM), NCDs, Kenya, Sub-Saharan AfricaBackground
Diabetes mellitus (DM) is a chronic debilitating non-
communicable disease (NCD). In 2011, 366 million indi-
viduals had DM, a number that is projected to rise to
552 million by 2030, unless preventive interventions are
put in place [1]. Approximately 80% of the burden of* Correspondence: dunmatheka@gmail.com
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reproduction in any medium, provided the orDM is in the low-and middle-income countries, and it is
growing [1]. In one such country (Kenya), the prevalence
of DM has risen from 3.3% in 2007 to 4.2% in 2009, with
prevalence rates of up to 10% in some regions [1,2].
The HbA1C test is an indicator of average blood
glucose concentrations over the preceding three months.
It is a well-established biomarker of long-term glucose
control and was approved by the World Health
Organization (WHO) for the diagnosis of DM and mon-
itoring glycemic control in people with diabetes [3,4].
Higher HbA1C levels (recommended levels should bel Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of diabetic complications, and such an association is not
apparent with usual blood glucose tests [5,6].
Despite its value, the HbA1C test is not widely available
in Kenya due to its high cost. Although HbA1C test is
one of the recommended tests in the Kenyan national
clinical guidelines [7], most hospitals have no HbA1C
guidelines in place. Moreover, it is not offered in most
rural facilities. For these reasons, the required testing of
2 to 4 times a year may be impossible for most diabetic
patients in Kenya; hence, there is a need to assess pa-
tients’ knowledge and frequency of its use [8].
Health literacy among diabetic patients has been asso-
ciated with better glycemic control, optimal medication
and enhanced individual participation in diabetes self-
care [9,10]. Heisler et al. [9] reported that respondents
who knew their HbA1C values had better understanding
of diabetes care and assessment of their glycemic control
than those who did not. Moreover, the lack of awareness
may hinder health promotion strategies currently being
implemented in Kenya, including screening and media
campaigns that assume minimal awareness of such tests.
The current study therefore aimed to establish the
state of awareness of the HbA1C test as well as its use
among a subset of patients attending the outpatient dia-
betes clinic at the Kenyatta National Hospital (KNH), a
major referral and teaching hospital in Kenya.Methods
A cross-sectional descriptive study was conducted be-
tween October and November 2012 at the outpatient
diabetes clinic of KNH. The hospital has a daily out-
patient diabetes clinic with a daily turnover of approxi-
mately 20-30 patients, except on Fridays, when there is a
major diabetes clinic with a larger turnover. Data were
collected on three days of each week (Monday, Tuesday,
and Thursday) and patients present on the three days
were randomly selected to participate in the study.
One hundred and ninety eight adult type I and II dia-
betic patients (59 male and 139 female) agreed to partici-
pate in the study (response rate: 100%). All participants
attended regular follow-up sessions at the diabetes out-
patient clinic over the study’s two-month period; and were
randomly interviewed before their clinic visit by one of
the 3 interviewers (the authors) using a researcher-filled
questionnaire. Caution was also taken to ensure that a
respondent was not interviewed more than once over the
two-month study period. Ethical approval was obtained
from the Kenyatta National Hospital-Ethics and Research
Committee (KNH-ERC/UA/66). The study protocol was
explained to each of the patients, and consenting partici-
pants were asked to sign a consent form prior to their
interview.Information was gathered on the patients’ demo-
graphic details, level of literacy, type of DM, duration
and control of their DM. The patients were also inter-
viewed on their level of knowledge and their practices as
appertained to the HbA1C test, as well as their last
HbA1C level. This was through a series of short and sim-
ple self-reported questions that included: “1. Have you
ever heard about HbA1C? (Yes, No, Unknown) 2. Have
you ever done an HbA1C test? (Yes, No, Unknown) 3.
What was your last HbA1C level?” No previous article
known to the authors had utilized such an assessment
or questions. The respondent answers offered after the
above key questions were tabulated, analyzed and sum-
marized using SPSS version 16. The sample mean,
standard deviation and percentages were calculated.Results
The age of the participants ranged from 20 to 82 years
with a mean age of 53.1 ± 0.92 years. Fifty-two patients
(26.3%) lived in rural Kenya, while 146 (73.7%) resided
in urban areas. Twenty-seven patients (13.6%) had a ter-
tiary level of education, 79 (39.9%) had attained second-
ary level of education, and 80 (40.4%) had schooled up
to primary school level, while 12 (6.1%) had no formal
education. The duration of DM ranged from 6 months
to 30 years, with 50% of the patients having less than
6 years since diagnosis of their DM. Twenty-five percent
of the patients had DM for more than 11 years. Of the
patients interviewed, 11 (5.6%) had type I DM, while 187
(94.4%) had type II DM. However, of these patients, only
115 (58.1%) were aware of the type of DM they had been
diagnosed with. Of these 115 patients, 11 (9.6%) had
type I DM, while 104 (90.4%) had type II DM.
Of all the patients, 134 (67.7%) had heard of the
HbA1C test while 64 patients (32.3%) had never heard of
the test. Forty patients (20.2%) had at one point done
the test while 158 (79.8%) had never done the test. All
40 patients who had done the test were type II DM pa-
tients, with 20 (50%) being male and 20 (50%) female.
These 40 patients had a mean age of 55.8 years, and an
average of 7.7 years after DM diagnosis. The overall
mean HbA1C among those who had done the test was
8.5 ± 1.7%, with more than 90% having HbA1C > 8%.Discussion
We performed the first study of the frequency and
knowledge of HbA1C testing among diabetic patients in
Kenya. Using a sample of diabetes patients at the KNH,
we found that only 20% of patients had ever done at
least one HbA1C check. Among those who did the test,
the average HbA1C level was high (more than 90% had
HbA1C > 8%). Moreover, we found that only 67.7% of pa-
tients interviewed had heard of the HbA1C test. Checks
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type II diabetic patients.
HbA1C quarterly measurement combined with daily home
blood glucose monitoring forms the gold standard of
glycemic control in clinical practice [4]. However, HbA1C
monitoring is easier said than done, especially in developing
countries like Kenya, due to cost constraints [3,4,11].
Currently, HbA1C testing by outpatients in Kenya is paid
for by the patient and is not covered by the national insur-
ance. Published reports indicate that the average cost of an
HbA1C test in Kenya is US$10 in public health facilities and
up to US$25 in private facilities [3]. This cost is prohibitive in
a country where 50% of the residents live on less than US$1 a
day [11,12] and also contributes to its low availability [4]. The
absence of a proper national health insurance plan in Kenya
also makes HbA1C financially burdensome. This could
explain why a vast majority of our study subjects (80%) had
never had the test done. These results are comparable to
those of a similar study conducted inNigeria [13].
Increasing awareness of the test is important. Our study
found that a relatively high percentage of diabetes patients
had never heard of the test (>30%). One reason for this
may be that outpatient HbA1C testing is not part of the
package of essential medicines and diagnostics covered by
the government through national insurance, and thus is
not advertised as being available. This may also be a reflec-
tion of the lack of awareness of its utility, as well as the
availability of the test among the caregivers coming into
contact with the patient. Previous studies have shown that
caregivers are the primary sources of information about
diabetes to their patients [14].
The relatively low level of awareness of the test as well
the low frequencies of testing are noteworthy, particu-
larly since the patient cohort was obtained from a major
teaching and referral hospital where one would ordinar-
ily expect cutting edge therapeutic and disease manage-
ment approaches to be adopted as a matter of course.
Further, this is an indication that the situation in lower
level health facilities may actually be worse than what is
documented in this study. There is a need to carry out
studies to document the level of awareness, skill and
attitudes among Kenyan health professionals on the
HbA1C test in lower level health care facilities and assess
existence of relevant training programs initiated to remedy
any identified knowledge gaps. Furthermore, a widespread
rollout of subsidized or free HbA1C testing in all govern-
ment health facilities would ensure integration of this test
in diabetes management regimens. This is so as to ensure
the optimal glycemic control in all patients and hence
prevent the development of diabetic complications.
The reported high HbA1C levels (8.5 ± 1.7%), among
the 40 patients who had undergone testing in our study
are indicative of poor glycemic control that often leads
to the development of diabetic complications [8,15]. Inthese 40 patients with information on their HbA1C level,
over 90% had poor glycemic control (HbA1C > 7%). This
suggests that poor glycemic control may also be a prob-
lem among those not tested. This may be a reflection of
the use of treatment regimens or dosages of sub-optimal
efficacy and/or poor drug compliance by the patients. It
may also reflect a misconception among caregivers that
this test should only be used in patients with more
serious disease instead of being used in routine manage-
ment as recommended.
Lastly, besides concerns on the reliability of self-
reported data by the participants, results from this study
suggest that a small proportion of diabetic patients at
KNH have received health education regarding HbA1C.
There is also a possibility that HbA1C tests may have
been done without the knowledge of the patients, and
that their results were not discussed with the doctor.
Increased patient involvement and proper communica-
tion on the part of health care providers, as well as
discussion to ensure that the patients understand their
management, is critical. With HbA1C approval for gly-
cemic monitoring, health care providers need to educate
their patients on its role too [10]. Our future research in
this area will focus on patient follow up and outcomes
with appropriate HbA1C testing. Moreover, we will focus
on studying the patterns of HbA1C testing in each type
of DM, since it can be noticed that most patients inter-
viewed in the current study (94.4%) had type II DM.Conclusion
The results of the current study indicate inadequate
knowledge and monitoring of blood glucose control
among diabetic patients in Kenya using the HbA1C test.
This signals a lack of access to care and low public
awareness about the test and may lead to increased sus-
ceptibility to the development of diabetic complications
among these patients. The consequences include in-
creasing healthcare costs in a population facing a double
burden of disease. It is our recommendation that policy
makers focus on strategies that address HbA1C test ac-
cessibility in Kenya, including financial coverage by the
national insurance to access the test in public facilities,
so as to effectively monitor and combat DM. We also
call for streamlining of the healthcare infrastructure and
national health insurance towards coverage of outpatient
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